Sugi Predict

Sugi Predict / Compounds / SCHEMBL18683

SCHEMBL18683

SCHEMBL18683

CC[C@H]1CN(C(=O)OC(C)(C)C)CCN1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ PARP1 P09874 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37
▸ SCN9A Q15858 2/20 0.36
▸ EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2799343 1.00 NR1H2 (0.43) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL334410 1.00 NR1H2 (0.43) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL6981501 0.91 MEN1 (0.46) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL20742255 0.89 NR1H2 (0.40) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL20742257 0.89 NR1H2 (0.40) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL29476305 0.89 NR1H2 (0.40) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL10219106 0.88 NR1H2 (0.41) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL1468234 0.88 NR1H2 (0.41) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL10219104 0.88 NR1H2 (0.41) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL1462710 0.88 NR1H2 (0.50) NR1H2MAPTMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 — — US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 — — EP claimed
US-12637458-B2 Imidazo[1,2-a]pyridine compounds and their use in therapy IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2026-05-26 — — US disclosed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 — — WO disclosed
EP-4687883-A2 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE Caraway Therapeutics, Inc. (US) 2026-02-11 — — EP disclosed
US-12545670-B2 Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2026-02-10 — — US disclosed
EP-4157836-B1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INT (DE) 2025-10-29 — — EP disclosed
US-20250304568-A1 PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE ABBVIE INC (US) 2025-10-02 — — US disclosed
US-20250002485-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INT (DE) 2025-01-02 — — US disclosed
EP-4480482-A2 PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE AbbVie Inc. (US) 2024-12-25 — — EP disclosed
US-12172992-B2 Pyrimidines for degrading Bruton's tyrosine kinase ABBVIE INC. (US) 2024-12-24 — — US disclosed
US-20100216812-A1 Cyclopropyl Amide Derivatives ASTRAZENECA AB (SE) 2010-08-26 — — US disclosed
CN-101600720-A Phosphoinositide 3-kinase inhibitor compounds and using method HOFFMANN LA ROCHE (CH) 2009-12-09 — — CN disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 — — US disclosed
EP-1343775-B1 PIPERAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-06-04 — — EP disclosed
US-7022707-B2 Piperazine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-04-04 — — US disclosed
US-20040235859-A1 Novel piperazine derivatives ADAMS DAVID REGINALD (GB) 2004-11-25 — — US disclosed
EP-1343775-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-17 — — EP disclosed
US-20020143020-A1 Novel piperazine derivatives VERNALIS RESEARCH LIMITED (GB) 2002-10-03 — — US disclosed
WO-2002048124-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304568-A1 PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE BTK, TYMP, LYN NR1H2 3306/4885MAPT 4765/4885MEN1 4061/4885
US-12545670-B2 Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer KRAS, HRAS, NRAS NR1H2 3046/4885MAPT 4840/4885MEN1 2616/4885
US-20020143020-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 NR1H2 1100/4885MAPT 2976/4885MEN1 1694/4885
US-20100216812-A1 Cyclopropyl Amide Derivatives HRH4, HRH2, HRH3 NR1H2 63/4885MAPT 1670/4885MEN1 3982/4885
US-20090286974-A1 Derivative having ppar agonistic activity PPARD, PPARA, PPARG NR1H2 9/4885MAPT 4787/4885MEN1 4624/4885
US-20250002485-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER RSU1, KRAS, NRAS NR1H2 4740/4885MAPT 4242/4885MEN1 897/4885
US-12172992-B2 Pyrimidines for degrading Bruton's tyrosine kinase BTK, TYMP, LYN NR1H2 3306/4885MAPT 4765/4885MEN1 4061/4885
US-12637458-B2 Imidazo[1,2-a]pyridine compounds and their use in therapy OGFR, CBR3, CBR1 NR1H2 242/4885MAPT 4454/4885MEN1 1503/4885
US-20040235859-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 NR1H2 1100/4885MAPT 2976/4885MEN1 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.